MX342882B - Compuestos de sulfonamida que tienen actividad antagonista de canales de potencial de receptor transitorio melastatina 8. - Google Patents
Compuestos de sulfonamida que tienen actividad antagonista de canales de potencial de receptor transitorio melastatina 8.Info
- Publication number
- MX342882B MX342882B MX2013010572A MX2013010572A MX342882B MX 342882 B MX342882 B MX 342882B MX 2013010572 A MX2013010572 A MX 2013010572A MX 2013010572 A MX2013010572 A MX 2013010572A MX 342882 B MX342882 B MX 342882B
- Authority
- MX
- Mexico
- Prior art keywords
- monocyclic
- ring
- aromatic heterocycle
- bicyclic
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos de sulfonamida que tienen actividad antagónica de TRPM8; un compuesto de sulfonamida de la fórmula (I) o una sal farmacéuticamente aceptable del mismo, o un profármaco del mismo: (Ver Formula) en donde el Anillo A es heterociclo aromático bicíclico comprendido de (a) piridina se condensa con benceno; o (b) piridina se condensa con heterociclo aromático monocíclíco, y el Anillo A se une a una porción sulfonilamino en un átomo de carbono adyacente a un átomo de nitrógeno del anillo piridina que constituye el Anillo A; el Anillo B es (a) un hidrocarburo aromático monocíclico o bicíclico; (b) un hidrocarburo alicíclico monocíclíco o bicíclico; (c) heterociclo aromático monocíclíco o bicíclico; o (d) heterociclo no aromático monocíclíco o bicíclico; el anillo C es (a) benceno; o (b) heterociclo aromático monocíclico, y los otros símbolos son igual como se definió en la especificación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453396P | 2011-03-16 | 2011-03-16 | |
PCT/JP2012/057412 WO2012124825A1 (en) | 2011-03-16 | 2012-03-15 | Sulfonamide compounds having trpm8 antagonistic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013010572A MX2013010572A (es) | 2013-10-03 |
MX342882B true MX342882B (es) | 2016-10-14 |
Family
ID=45932480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010572A MX342882B (es) | 2011-03-16 | 2012-03-15 | Compuestos de sulfonamida que tienen actividad antagonista de canales de potencial de receptor transitorio melastatina 8. |
Country Status (17)
Country | Link |
---|---|
US (2) | US8987445B2 (es) |
EP (1) | EP2686302B1 (es) |
JP (1) | JP5684401B2 (es) |
KR (1) | KR101638672B1 (es) |
CN (1) | CN103443080B (es) |
AU (1) | AU2012229813B2 (es) |
BR (1) | BR112013023330B8 (es) |
CA (1) | CA2826678C (es) |
DK (1) | DK2686302T3 (es) |
ES (1) | ES2588752T3 (es) |
HU (1) | HUE031585T2 (es) |
MX (1) | MX342882B (es) |
PL (1) | PL2686302T3 (es) |
PT (1) | PT2686302T (es) |
RU (1) | RU2563030C2 (es) |
TW (1) | TWI519520B (es) |
WO (1) | WO2012124825A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103443080B (zh) | 2011-03-16 | 2016-10-12 | 田边三菱制药株式会社 | 具有trpm8拮抗活性的磺酰胺化合物 |
JP6127056B2 (ja) * | 2012-09-14 | 2017-05-10 | 田辺三菱製薬株式会社 | スルホンアミド化合物 |
JP5985453B2 (ja) * | 2012-09-14 | 2016-09-06 | 田辺三菱製薬株式会社 | 医薬組成物 |
CN102924344A (zh) * | 2012-10-10 | 2013-02-13 | 北京康正康仁生物科技有限公司 | 丙磺舒钠、丙磺舒钾的合成制备方法 |
EP2774919A1 (en) * | 2013-03-06 | 2014-09-10 | Pharmeste S.R.L. In Liquidazione | Novel sulfonamide TRPA1 receptor antagonists |
EP2995611B1 (en) | 2013-05-08 | 2017-10-11 | Kissei Pharmaceutical Co., Ltd. | Alpha-substituted glycineamide derivative |
TW201605852A (zh) * | 2013-09-26 | 2016-02-16 | 美國禮來大藥廠 | 新穎化合物及其製備tau造影劑及tau造影調配物之用途 |
CN104529895B (zh) * | 2014-12-11 | 2017-02-08 | 温州大学 | 一种取代含氮杂环化合物的合成方法 |
CN104557701B (zh) * | 2014-12-11 | 2016-05-04 | 温州大学 | 一种异喹啉衍生物的制备方法 |
CN105315357A (zh) * | 2015-10-14 | 2016-02-10 | 韩蕾 | Trpm8蛋白和相关多肽片段及其抗体的新用途 |
KR20230143623A (ko) * | 2016-03-28 | 2023-10-12 | 로즈데일 다이나믹스 엘엘씨 | 인터 예측 모드 기반 영상 처리 방법 및 이를 위한 장치 |
CN109310689A (zh) * | 2016-06-13 | 2019-02-05 | 田边三菱制药株式会社 | 用于治疗或预防血管舒缩症状的组合物 |
JP7265551B2 (ja) | 2017-12-19 | 2023-04-26 | 田辺三菱製薬株式会社 | 血管運動症状を治療または予防するための組成物および方法 |
JP6985137B2 (ja) * | 2017-12-27 | 2021-12-22 | 田辺三菱製薬株式会社 | スルホンアミド化合物の結晶形 |
US10553537B2 (en) * | 2018-02-17 | 2020-02-04 | Sandisk Technologies Llc | Interconnects containing serpentine line structures for three-dimensional memory devices and methods of making the same |
RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
RU2726793C1 (ru) * | 2020-02-12 | 2020-07-15 | Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр "КОМИ научный центр Уральского отделения Российской академии наук" | Хиральные 18-сульфопроизводные дегидроабиетана и способ их получения |
CN115784857B (zh) * | 2022-12-09 | 2024-05-24 | 长沙贝塔医药科技有限公司 | 一种4-氟苯基环丙基甲酮-14c及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952722A (en) | 1982-02-12 | 1990-08-28 | Ici Australia Limited | Compounds and compositions |
DE19831878C2 (de) | 1998-07-17 | 2001-05-17 | Aventis Pharma Gmbh | Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US20070043014A1 (en) | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
KR100926842B1 (ko) * | 2004-07-28 | 2009-11-13 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd1 억제제로서의 아릴-피리딘 유도체 |
AU2005268893B2 (en) | 2004-08-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Indole, indazole or indoline derivatives |
WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
PA8790401A1 (es) * | 2007-07-18 | 2009-03-31 | Janssen Pharmaceutica Nv | Sulfonamidas como moduladores de trpm8 |
EP2426109B1 (en) | 2007-10-23 | 2013-12-18 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
WO2010010435A2 (en) * | 2008-07-22 | 2010-01-28 | Glenmark Pharmaceutical S.A. | Fused oxazole and thiazole derivatives as trpms modulators |
WO2010089686A1 (en) | 2009-02-04 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
KR20140071518A (ko) * | 2009-05-01 | 2014-06-12 | 라퀄리아 파마 인코포레이티드 | Trpm8 길항제로서의 설파모일 벤조산 유도체 |
TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
WO2012042915A1 (en) | 2010-10-01 | 2012-04-05 | Raqualia Pharma Inc. | Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists |
EP2649072A1 (en) | 2010-12-09 | 2013-10-16 | Janssen Pharmaceutica, N.V. | Imidazo [1, 2-a]pyridine sulfonamides as trpm8 modulators |
CN103443080B (zh) | 2011-03-16 | 2016-10-12 | 田边三菱制药株式会社 | 具有trpm8拮抗活性的磺酰胺化合物 |
-
2012
- 2012-03-15 CN CN201280013559.7A patent/CN103443080B/zh active Active
- 2012-03-15 US US14/004,911 patent/US8987445B2/en active Active
- 2012-03-15 MX MX2013010572A patent/MX342882B/es active IP Right Grant
- 2012-03-15 KR KR1020137027128A patent/KR101638672B1/ko active IP Right Grant
- 2012-03-15 PL PL12712777T patent/PL2686302T3/pl unknown
- 2012-03-15 JP JP2013541123A patent/JP5684401B2/ja active Active
- 2012-03-15 EP EP12712777.7A patent/EP2686302B1/en active Active
- 2012-03-15 DK DK12712777.7T patent/DK2686302T3/en active
- 2012-03-15 ES ES12712777.7T patent/ES2588752T3/es active Active
- 2012-03-15 CA CA2826678A patent/CA2826678C/en active Active
- 2012-03-15 HU HUE12712777A patent/HUE031585T2/en unknown
- 2012-03-15 AU AU2012229813A patent/AU2012229813B2/en active Active
- 2012-03-15 BR BR112013023330A patent/BR112013023330B8/pt active IP Right Grant
- 2012-03-15 RU RU2013146011/04A patent/RU2563030C2/ru active
- 2012-03-15 WO PCT/JP2012/057412 patent/WO2012124825A1/en active Application Filing
- 2012-03-15 PT PT127127777T patent/PT2686302T/pt unknown
- 2012-03-16 TW TW101109074A patent/TWI519520B/zh active
-
2015
- 2015-02-12 US US14/620,360 patent/US9540360B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201300362A (zh) | 2013-01-01 |
ES2588752T3 (es) | 2016-11-04 |
CA2826678A1 (en) | 2012-09-20 |
EP2686302B1 (en) | 2016-08-10 |
HUE031585T2 (en) | 2017-07-28 |
MX2013010572A (es) | 2013-10-03 |
RU2563030C2 (ru) | 2015-09-20 |
US20140005393A1 (en) | 2014-01-02 |
KR101638672B1 (ko) | 2016-07-11 |
WO2012124825A1 (en) | 2012-09-20 |
CN103443080A (zh) | 2013-12-11 |
JP5684401B2 (ja) | 2015-03-11 |
JP2014508105A (ja) | 2014-04-03 |
CN103443080B (zh) | 2016-10-12 |
BR112013023330B8 (pt) | 2022-09-27 |
US20150218143A1 (en) | 2015-08-06 |
PL2686302T3 (pl) | 2017-01-31 |
AU2012229813B2 (en) | 2015-09-03 |
AU2012229813A1 (en) | 2013-08-29 |
US8987445B2 (en) | 2015-03-24 |
PT2686302T (pt) | 2016-11-02 |
US9540360B2 (en) | 2017-01-10 |
BR112013023330B1 (pt) | 2021-09-08 |
RU2013146011A (ru) | 2015-04-27 |
KR20140011385A (ko) | 2014-01-28 |
BR112013023330A2 (pt) | 2017-07-18 |
CA2826678C (en) | 2016-07-26 |
TWI519520B (zh) | 2016-02-01 |
DK2686302T3 (en) | 2016-10-24 |
EP2686302A1 (en) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX342882B (es) | Compuestos de sulfonamida que tienen actividad antagonista de canales de potencial de receptor transitorio melastatina 8. | |
MX2014001687A (es) | Compuestos heterociclicos triciclicos inhibidores de jak. | |
PH12017501426A1 (en) | Derivatives of betulin | |
PH12015500360A1 (en) | Pyrazolopyrimidine compound | |
AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
BR112014003587A2 (pt) | derivados de 5-flúor-4-imino-3-(substituído)-3,4-di-hidropirimidin-2(1h)ona | |
EA201201377A1 (ru) | Определенные аминопиридазины, композиции на их основе и способы их использования | |
EA201700230A1 (ru) | Определенные аминопиридины, композиции на их основе и способы их применения | |
EA201070876A1 (ru) | Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции | |
TN2015000261A1 (fr) | Dérivés d'imidazopyridazine servant de modulateurs des recepteurs gabaa | |
IN2014DN07509A (es) | ||
EA201290397A1 (ru) | 1,3,4-оксадиазол-2-карбоксамидное соединение | |
EA201590319A1 (ru) | Новые бициклические пиридиноны | |
EA201492255A1 (ru) | Феноксиэтилпиперидиновые соединения | |
WO2012042534A3 (en) | Preparation of r-sitagliptin and intermediates thereof | |
CA2873723A1 (en) | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase | |
WO2011143772A9 (en) | Inhibitors of hiv replication | |
MX2017005422A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
WO2012062901A3 (en) | Chromene derivatives and their analoga as wnt pathway antagonists | |
IN2015DN03235A (es) | ||
PH12016502091A1 (en) | Novel bicyclic or tricyclic heterocyclic compound | |
MX2014015345A (es) | Inhibidores piranopiridona de tanquirasa. | |
WO2014062428A8 (en) | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |